Jose Vasquez, MD
Infectious Disease · Brandon, FLNPI 1184667198
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.6% of the total across 234 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,125, 4.7 times the $451 reported in 2019.
Across 234 payments — averaging $25.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$1K
- AbbVie$871
- Viiv Healthcare Company$815
- Melinta Therapeutics, LLC$775
- Merck$452
- Gilead$341
- plus $1K from 13 others
Across 1 payment — averaging $2700.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$3K
What the payments were for
- Food & beverage$5,61495%
- Education$3225%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 45 | $1,201 |
| AbbVie | 32 | $871 |
| Viiv Healthcare Company | 35 | $815 |
| Melinta Therapeutics, LLC | 24 | $775 |
| Merck | 22 | $452 |
| Gilead | 16 | $341 |
| Astellas Pharma US Inc | 5 | $254 |
| Aimmune Therapeutics, Inc. | 14 | $250 |
| La Jolla Pharmaceutical Company | 7 | $212 |
| Ferring Pharmaceuticals Inc. | 3 | $207 |
| Paratek Pharmaceuticals, Inc. | 9 | $177 |
| Shionogi Inc | 8 | $162 |
| Johnson & Johnson | 5 | $71 |
| Electromed, Inc. | 4 | $57 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $30 |
| Grifols USA, LLC | 1 | $20 |
| Convatec Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| Theratechnologies Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,936 in reported general payments places this provider in the 80th percentile of 669 infectious disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 88 | $352,144 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 23 | $266,634 |
| NuzyraOmadacycline Tosylate | 13 | $252,945 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 11 | $145,648 |
| CabenuvaCabotegravir/Rilpivirine | 14 | $98,462 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 16 | $65,533 |
| DovatoDolutegravir Sodium/Lamivudine | 17 | $48,657 |
| TivicayDolutegravir Sodium | 21 | $45,174 |
| Daptomycin | 16 | $33,690 |
| DescovyEmtricitabine/Tenofov Alafenam | 13 | $26,945 |
| IsentressRaltegravir Potassium | 12 | $21,479 |
| Rifabutin | 39 | $20,821 |
| ErtapenemErtapenem Sodium | 18 | $11,225 |
| Meropenem | 29 | $3,691 |
| Vancomycin Hcl | 19 | $3,395 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $341 | $444,622117 claims |
| Paratek Pharmaceuticals, Inc.Nuzyra | $177 | $252,94513 claims |
| Viiv Healthcare CompanyCabenuva, Dovato, Tivicay | $815 | $192,29352 claims |
| MerckIsentress | $452 | $21,47912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 669 infectious disease providers in Florida.
Other infectious disease in Brandon
- Lennox ArchibaldGainesville$2.1M
- Moti RamgopalFort Pierce$1.1M
- Juan DiazAltamonte Springs$980K
- Charlotte-Paige RolleOrlando$619K
- Kenneth AlexanderOrlando$474K
- Douglas BrustMiami$359K
- Christopher CooperAltamonte Springs$278K
- Federico HinestrosaOrlando$276K
- Cynthia RiveraMiami Beach$265K
- Sally AlrabaaTampa$250K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.